相关实验视频

Updated: Mar 3, 2026

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Author Spotlight: Obtaining High-Quality CSF and Blood Samples for Epilepsy Biomarker Discovery

Published on: September 1, 2023

使用机器学习和真实世界的数据预测患者的 levetiracetam 血度

Bolin Zhu¹, Nan Zheng¹, Di Chen¹

¹Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing, China.

Therapeutic advances in psychopharmacology

|March 2, 2026

概括

机器学习模型可以预测患者的 levetiracetam 血度. 极端梯度提升 (XGBoost) 算法显示出最佳性能,每日剂量是关键因素.

科学领域:

药物基因组学药物基因组学
临床药房临床药房
人工智能在医学中的应用

背景情况:

列维他是一种关键的抗药物,但其疗效因个人因素而异.
治疗药物监测 (TDM) 对于优化中 levetiracetam 治疗至关重要.
预测 levetiracetam 度的机器学习 (ML) 应用尚未得到充分研究.

研究的目的:

开发和评估ML模型,用于预测患者中 levetiracetam 度.
创建一个网络应用程序,以帮助临床医生调整 levetiracetam 剂量.
为了确定影响莱维他血水平的关键因素.

主要方法:

对接受 levetiracetam 治疗的 153 名患者的回顾性分析.
从47个变量中使用顺序前置选择进行特征选择.
ML模型的比较,XGBoost被选为最佳预测器.
使用夏普利添加式解释 (SHAP) 评估的重要变量.

主要成果:

在XGBoost模型中,R2=0.50,MAE=0.43和RMSE=0.58.5是可以实现的.
11个变量被确定为最佳预测因素.
每日剂量,年龄,UREA,URIC和血红蛋白是重要的因素.
每日剂量表明对 levetiracetam 度产生最显著的积极影响.

结论:

XGBoost是一个有价值的AI工具,用于预测 levetiracetam 度.
每日剂量和年龄是血清中 levetiracetam 水平的显著预测指标.
这项研究提供了现实世界的数据和指导,用于临床 levetiracetam 剂量调整.

关键词:

是一种.莱维泰拉塞坦 ( levetiracetam) 的使用情况机器学习是机器学习.现实世界的研究研究.治疗药物监测治疗药物监测

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

A Model for Epilepsy of Infectious Etiology using Theiler's Murine Encephalomyelitis Virus

Published on: June 23, 2022

相关概念视频

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...

Epilepsy and Seizures: Overview

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...

Seizures: Classification

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types: